Skip to main content
. 2019 May 17;105(2):387–397. doi: 10.3324/haematol.2019.219394

Figure 5.

Figure 5.

Dasatinib rescues BCR-ABL1p210 driven eye defect and shows target specificity in vivo. Scanning electron micrographs of adult Drosophila compound eyes from flies fed on 0.03% DMSO only or dasatinib. Posterior is to the left. GMR-GAL4>w1118 were used as control. E-H and M-P are high magnification of the posterior end of the eye in A-D and I-L respectively (692x). Normal development in control flies fed on DMSO (A,E, I, M) or dasatinib is observed. BCR-ABL1p210 (C, G) and BCR-ABL1p210/T315I (K, O) expressing flies fed on DMSO show characteristic defective area with loss of ommatidial facets. Area is marked with a representative dashed line. Ommatidial development in this area was restored with BCR-ABL1p210 flies fed on 20 mM dasatinib (D, H). Compare to (C, G). BCR-ABLp210/T315I flies showed no restoration of ommatidial development (L, P). Compare to (K, O). Lower left panel represents measurement of the posterior eye defect area (mm2). Data represents mean ± SEM. ****, P<0.0001. Lower right panel is a representative Western blot of the expression of BCR-ABL1 and phosphorylated levels in transgenic untreated and treated adult fly heads. Genotypes indicated are under the control of eye specific promoter GMR-GAL4.